November 6, 2016. Since sugammadex has the ability to quickly reverse the paralysis induced by neuromuscular blockers like rocuronium, it represents an innovative new option to improve surgical recovery. However, as with every new drug, we need to be certain the benefits outweigh the harms.
Read More »On Medical Treatments & Products
NCHR Testimony at FDA Advisory Committee on Cholesterol Drug Alirocumab
June 9, 2015. We are asking you to reject approval of this drug for women and people of color until and unless subgroup analyses indicate the benefits outweigh the risks for those populations.
Read More »NCHR Testimony Before FDA Advisory Panel on Flibanserin
June 4, 2015. The Center strongly supports research to advance understanding of, and solutions to, women’s lack of sexual desire. We understand that it is a real and distressing problem for many women. We have followed the regulatory history of flibanserin. Based on our analysis of the study results available today, we conclude that the benefits of this drug do not outweigh the risks. We ask the Advisory Committee to vote against approval of this drug.
Read More »Comments to the U.S. Consumer Product Safety Commission on Corded Window Coverings
June 1, 2015. We submit these comments in strong support of the U.S. Consumer Product Safety Commission’s (CPSC) development of a mandatory standard that prohibits hazardous, accessible window covering cords. A mandatory standard is needed because the current voluntary standard, which relies on warnings, has not significantly reduced the death rate.
Read More »Letter to Chairwoman Alexander on E-cigarette Regulations in the District of Columbia
May 27, 2015. The popularity of e-cigarettes has risen because of claims from manufacturers that they are safer than conventional tobacco-containing cigarettes. However, they are still unsafe.
Read More »